Article
Identification of polymorphisms associated with hypertriglyceridemia and prolonged survival induced by bexarotene in treating non-small cell lung cancer.
Anticancer research - 1 Jun 2011
Luo Wen, Schork Nicholas J, Marschke Keith B, Ng Shi-Chung, Hermann Thomas W, Zhang Jinkun, Sanders Jennifer M, Tooker Patricia, Malo Nathalie, Zapala Matthew A, Dziewanowska Zofia E, Negro-Vilar Andres, Meglasson Martin D
Abstract excerpt
BACKGROUND: Bexarotene was evaluated in treating advanced non small cell lung cancer (NSCLC) in two phase III trials. Although a significant survival benefit was not observed for the overall bexarotene-treated population (617 patients), a third of bexarotene-treated patients who developed high-grade hypertriglyceridemia exhibited significantly longer survival. PATIENTS AND METHODS: In order to identify genomic...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.